| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/20/2005 | EP1523481A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 04/20/2005 | EP1523480A2 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 04/20/2005 | EP1523473A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 04/20/2005 | EP1523471A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 04/20/2005 | EP1523323A2 Reagents and methods for smooth muscle therapies |
| 04/20/2005 | EP1523316A2 Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
| 04/20/2005 | EP1523311A1 Calcium lactate and whey permeate for lowering the triglyceride level |
| 04/20/2005 | EP1523310A2 Method to inhibit ischemia and reperfusion injury |
| 04/20/2005 | EP1373249B1 Imidazolidine derivatives, their preparation, and their use as antiinflamatory agent |
| 04/20/2005 | EP1365737B1 Stable salts of o-acetylsalicyclic with basic amino acids |
| 04/20/2005 | EP1349847B1 Oxybenzamides derivatives as factor xa inhibitors |
| 04/20/2005 | EP1349843B1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 04/20/2005 | EP1318829B1 Angiogenic tri- or tetrapeptides derived from AcSDKP |
| 04/20/2005 | EP1307425B1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 04/20/2005 | EP1254133B1 Indol-3-yl derivatives and their use as integrin inhibitors |
| 04/20/2005 | EP1252158B1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| 04/20/2005 | EP1226110B1 Bicyclic amino acids as pharmaceutical agents |
| 04/20/2005 | EP1213290B1 Dihydrobenzofuran derivatives, process for the preparation thereof and agents |
| 04/20/2005 | EP1191935B1 Treatment or prevention of coronary graft vasospasm |
| 04/20/2005 | EP1178810B1 Use of bisphosphonic acids for treating angiogenesis |
| 04/20/2005 | EP1177185B1 4, 5, 6, 7-tetrahydroindazole derivatives as antitumor agents |
| 04/20/2005 | EP1144395B1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1143977B1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1129077B1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 04/20/2005 | EP1089968B1 Thyroid hormone analogues and methods for their preparation |
| 04/20/2005 | EP1076651B1 Substituted sulphonyl cyanamides, method for producing same and their use as medicament |
| 04/20/2005 | EP1042287B1 Indole derivatives as inhibitors of factor xa |
| 04/20/2005 | EP1009753B1 Hypoxia-regulated genes |
| 04/20/2005 | EP0805859B1 A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses |
| 04/20/2005 | EP0775213B1 Adenovirus comprising a gene coding for glutathion peroxidase |
| 04/20/2005 | EP0721455B9 Tetrahydropyridine-(or 4-hydroxypiperidine)alkylazoles having an affinity for sigma and/or 5ht1a receptors |
| 04/20/2005 | CN1608069A Selective androgen receptor modulators and methods for their identification, design and use |
| 04/20/2005 | CN1608068A Bridged bicyclic amino acid-derived [1, 4]benzodiazepine vasopressin receptor antagonists |
| 04/20/2005 | CN1608067A Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 04/20/2005 | CN1608065A Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase and pharmaceutical compositions containing the compounds |
| 04/20/2005 | CN1608063A Indolinone derivatives |
| 04/20/2005 | CN1608061A Therapeutic isoquinoline compounds |
| 04/20/2005 | CN1608056A Carboxylic acid derivative compounds and agents comprising the compounds as active ingredient |
| 04/20/2005 | CN1608055A Compounds for the treatment of metabolic disorders |
| 04/20/2005 | CN1608054A Therapeutic quinolone compounds with 5-HT-antagonistic properties |
| 04/20/2005 | CN1608053A Heterocyclic derivatives of glycinamide and its pharmaceutical uses |
| 04/20/2005 | CN1608051A Method of resolving amlodipine racemate |
| 04/20/2005 | CN1607960A Glycoprotein compositions |
| 04/20/2005 | CN1607957A Modulation of excitable tissue function by peripherally administered erythropoietin |
| 04/20/2005 | CN1607952A Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 04/20/2005 | CN1607951A Quinoline derivatives as neuropeptide y antagonists |
| 04/20/2005 | CN1607211A Poly asparaginyl aminoacetic acid, alanine and lysine and its preparation method and medicament purpose |
| 04/20/2005 | CN1606985A Beewax essence millimicrosphere preparation and its uses in medicine |
| 04/20/2005 | CN1197956C Lactobacillus helvetius producing antihypertensive di- and tripeptides |
| 04/20/2005 | CN1197849C 2, 3, 4, 5-tetrahydro-1H-[1, 4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
| 04/20/2005 | CN1197617C Fish serine proteinases and their pharmaceutical and cosmetic use |
| 04/20/2005 | CN1197600C Medicine for curing haemorrhoids |
| 04/20/2005 | CN1197594C Chinese traditional medicinal pill for treating cardiovascular and cerebrovascular disease |
| 04/20/2005 | CN1197585C Application of polygonatum polyscaccharide |
| 04/20/2005 | CN1197582C Preparation with haw leaf extractive as main effect composition |
| 04/20/2005 | CN1197567C Application of kaempferol derivative in preparing medicine for cerebrovascular diseases |
| 04/20/2005 | CN1197565C Method for preventing or delaying catheter-based revascularization |
| 04/20/2005 | CN1197481C Method for treatment of chronic venous functionalinsufficiencies using extract of red vine leaves |
| 04/19/2005 | US6881857 Tricyclic diterpene derivatives |
| 04/19/2005 | US6881854 Conjugated unsaturated glyceride mixtures and a method for producing the same |
| 04/19/2005 | US6881755 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| 04/19/2005 | US6881754 Adamantane derivatives |
| 04/19/2005 | US6881753 Potassium channel inhibitors and method |
| 04/19/2005 | US6881748 Drug targeting |
| 04/19/2005 | US6881743 Pyridine matrix metalloproteinase inhibitors |
| 04/19/2005 | US6881740 Pharmaceutical agents |
| 04/19/2005 | US6881739 Use of cortisol antagonists in the treatment of heart failure |
| 04/19/2005 | US6881735 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 04/19/2005 | US6881734 Pharmaceutical composition for the treatment of CNS and other disorders |
| 04/19/2005 | US6881730 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
| 04/19/2005 | US6881722 Polypeptide Saratin for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to novel |
| 04/19/2005 | US6881546 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
| 04/19/2005 | CA2315189C Integrin receptor antagonists |
| 04/19/2005 | CA2265252C Angiogenic factor and use thereof in treating cardiovascular disease |
| 04/14/2005 | WO2005033700A1 Method of screening insulin resistance-improving agent |
| 04/14/2005 | WO2005033115A1 New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| 04/14/2005 | WO2005033085A1 Pyrimidines derivatives as adenosine receptors ligands |
| 04/14/2005 | WO2005033084A1 Substituted pyrimidines as ligands of adenosine receptors |
| 04/14/2005 | WO2005033054A1 Reduced coenzyme q10 crystal excelling in stability and composition containing reduced coenzyme q10 crystal |
| 04/14/2005 | WO2005032563A1 Method for reducing vascular inflammation |
| 04/14/2005 | WO2005032559A1 Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
| 04/14/2005 | WO2005032535A1 Nerve regeneration promoters |
| 04/14/2005 | WO2005032533A1 Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent |
| 04/14/2005 | WO2005032462A2 Glucocerebroside treatment of disease |
| 04/14/2005 | WO2005002559A3 Methods of inhibiting vascular permeability and apoptosis |
| 04/14/2005 | WO2005000318A3 Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| 04/14/2005 | WO2004113515A3 Tissue modeling in embryonic stem (es) cell system |
| 04/14/2005 | WO2004098525A3 Uses of ion channel modulating compounds |
| 04/14/2005 | WO2004096257A8 Genetic modification of targeted regions of the cardiac conduction system |
| 04/14/2005 | WO2004094396A3 Dihydrothiazine prodrugs of thiazolium agents |
| 04/14/2005 | WO2004092215A3 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 |
| 04/14/2005 | WO2003051287A3 Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 04/14/2005 | WO2003027228A3 Receptors and membrane-associated proteins |
| 04/14/2005 | US20050080266 Nitrogen compounds such as 8,9-dihydroxy-1,2,3,11b-tetrahydro-chromeno(4,3,2-de)isoquinoline hydrobromide, administered for prophylaxis of nervous system disorders |
| 04/14/2005 | US20050080257 Benzo'fisoindole derivatives with affinity to the ep4 receptor |
| 04/14/2005 | US20050080120 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body |
| 04/14/2005 | US20050080119 Diaminopropionic acid derivatives |
| 04/14/2005 | US20050080117 Substituted benzoxazoles as estrogenic agents |
| 04/14/2005 | US20050080108 such as (S)-1-ethyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid-[2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]amide; for treatment of obesity and lipid disorders; diabetes |
| 04/14/2005 | US20050080107 Inhibitor of phosphodiesterase enzyme, 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid monohydrate; treating inflammatory diseases, diabetics, allergic diseases, autoimmune diseases, ocular diseases, osteoporosis, Parkinson's disease, dementia; chemical intermediates |